Répertoire du corps professoral

Investigation of neuroprotective and neurorescue properties of zuranolone in a mouse model of Parkinson’s disease
Programme: Programme de projets pilotes
Organisme(s) subventionnaire(s): Parkinson Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 août 2024 au 31 juillet 2025

Mechanisms of action of sex-specific endocrine treatments in complementary models of Parkinson's disease
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2024 au 31 mars 2029

Brain magnetic stimulation to reduce levodopa-induced dyskinesias in Parkinson’s disease
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2024 au 31 mars 2026

Financements des 2 dernières années

Mechanisms of action of sex-specific endocrine treatments in animal models of Parkinson's disease
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 mars 2023 au 29 février 2024

Relationship between COVID-19 and Parkinson’s disease in a mouse model
Programme: Programme de projets pilotes
Organisme(s) subventionnaire(s): Parkinson Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2022 au 31 mars 2024

Pregnenolone for the treatment of dyskinesia in Parkinson’s disease
Organisme(s) subventionnaire(s): Michael J. Fox Foundation for Parkinson's Research
Type de financement: Subvention
Établissement tête: Università Degli Studi Di Cagliari
Du 1 avril 2022 au 1 septembre 2024

Sex-specific investigations of Parkinson's disease mouse models: application for gonadal drugs repurposing
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2018 au 31 mars 2023

Amandine Isenbrandt, Doctorat en sciences pharmaceutiques

Encadrements terminés dans les 5 dernières années

Estelle Gouriou, Doctorat en neurosciences

Amandine Isenbrandt, Maîtrise en sciences pharmaceutiques - avec mémoire

Jordan Nadeau, Maîtrise en sciences pharmaceutiques - avec mémoire

Andrée-Anne Poirier, Maîtrise en sciences pharmaceutiques - avec mémoire

Andrée-Anne Poirier, Doctorat en sciences pharmaceutiques

Ahmed Nadhir Litim, Doctorat en sciences pharmaceutiques

Maria Gabriela Sanchez De Bédard, Doctorat en pharmacie

Nicolas Morin, Doctorat en pharmacie

Mélissa Maltais, Maîtrise en sciences pharmaceutiques - avec mémoire

Publications des 5 dernières années

Exploring Magnetic and Electrical Brain Stimulation in Parkinsonian Dyskinetic Monkeys Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2024/11/12. Estelle Gouriou, Mélanie Bourque, Cyril Schneider, Thérèse Di Paolo. DOI 10.1017/cjn.2024.284

Sex and Age Differences in a Progressive Synucleinopathy Mouse Model Biomolecules, 2023/06/11. Jérôme Lamontagne-Proulx, Katherine Coulombe, Marc Morissette, Marie Rieux, Frédéric Calon, Thérèse Di Paolo, Denis Soulet. DOI 10.3390/biom13060977

Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys Cells, 2022. DOI 10.3390/cells11040691

Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models Frontiers in Pharmacology, 2022. Poirier, A.-A., Côté, M., Jarras, H., Litim, N., Lamontagne-Proulx, J., Al-Sweidi, S., Morissette, M., Lachhab, A., Pelletier, M., Di Paolo, T., Soulet, D.. DOI 10.3389/fphar.2022.898067

Neuroactive steroids and Parkinson's disease Current opinion in endocrine and metabolic research., 2022. DOI 10.1016/j.coemr.2021.100312

Liquid chromatography coupled to tandem mass spectrometry methods for the selective and sensitive determination of 24S-hydroxycholesterol, its sulfate, and/or glucuronide conjugates in plasma Journal of mass spectrometry : JMS, 2022. DOI 10.1002/jms.4827

AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys Cells, 2022. Bourque, M., Grégoire, L., Patel, W., Dickens, D., Snodgrass, R., Di Paolo, T.. DOI 10.3390/cells11223530

Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease Frontiers in cellular neuroscience, 2021. DOI 10.3389/fncel.2021.670298

Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice Neuropharmacology, 2021. DOI 10.1016/j.neuropharm.2021.108784

Androgens and Parkinson's Disease: A Review of Human Studies and Animal Models Androgens: clinical research and therapeutics, 2021. DOI 10.1089/andro.2021.0011

Remodeling microglia to a protective phenotype in Parkinson's disease? Neuroscience letters, 2020. DOI 10.1016/j.neulet.2020.135164

Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease Journal of neuroendocrinology, 2020. DOI 10.1111/jne.12782

Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease Brain, behavior, and immunity, 2020. DOI 10.1016/j.bbi.2020.07.044

Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease Neuropharmacology, 2019. DOI 10.1016/j.neuropharm.2018.04.005

Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor Brain research, 2019. DOI 10.1016/j.brainres.2019.146460

Drug repurposing: Old drugs, new tricks to fast track drug development for the brain Neuropharmacology, 2019. DOI 10.1016/j.neuropharm.2019.01.009